Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNB1891 Monotherapy or with Atezolizumab in Advanced Solid Tumors and Lymphoma
NCT04167137Phase 1Terminated
- Sponsor
- Synlogic
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYNB1891 in solid tumor and lymphoma (2 arms), sponsored by Synlogic. Primary endpoint: Number of Participants With Dose-limiting Toxicity at 21 days. Started Dec 2019; status: terminated.
02
Drugs
SYNB1891
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT04167137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167137.